The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses what Amylyx’s FDA approved therapy means for the patient community and future research that may be performed regarding the dosage of the treatment. [WATCH TIME: 5 minutes]
In an open-label extension trial, tofersen showed significant reductions in SOD1 protein and neurofilament light over a 12-month period. It is now expected to be reviewed by the FDA by early Q2 2023.
Chaired by Robert T. Naismith, MD, this NeurologyLive® State of the Science Summit will be held virtually at 6:30 PM CST on November 3, 2022. Register for free now!
Here's some of what is coming soon to NeurologyLive® this week.
The launch of the medication was done in phases, as wholesalers received first-line formulary coverage in September 2022, while a nationwide launch is expected in 2023.
The professor of Neurology and Pediatrics at University of Rochester Medical Center speaks spoke on the evolving treatments for Duchenne muscular dystrophy and the possibility of earlier diagnosis through newborn screening. [WATCH TIME: 4 minutes]
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.
A report on two patients with late-onset neutropenia resulted in an uncommon adverse event following anti-CD20 therapies.
P100 amplitude of 15 minute checks in the NMOSD-ON group had a significant reduction at 6 months relative to the IDON group, suggesting more several axonal damage.
Neurology News Network for the week ending October 15, 2022. [WATCH TIME: 3 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 14, 2022.
A study conducted via telemonitoring showed that hospital workers who performed night shifts had significant negative impacts on their sleep quality and circadian rhythms.
The associate professor at the University of Michigan described the ways recently published guidelines on diabetic neuropathies will change how conditions like Guillain-Barré syndrome and CIDP are managed. [WATCH TIME: 3 minutes]
Over a 2-year treatment period, discontinuation rates with risdiplam were low, and observed adverse events and serious AEs resembled previously conducted studies.
A survey based on young adult college students indicated that symptoms of insomnia might buffer the association with the acute physiological effects of alcohol, in part because it may heighten the sensitivity to alcohol.
The clinical professor at the University at Buffalo discussed the complexities of using combination therapies to treat myasthenia gravis, and whether adverse events play a major role in treatment decisions. [WATCH TIME: 3 minutes]
AUPN Leading Edge Episode 4 features Rohit Das, MD, and Joseph R. Berger, MD, who discuss how neurologists are undervalued in academic and non-academic settings when their compensation is predicated on RVUs alone. [LISTEN TIME: 26 minutes]
Annualized relapse rates were elevated compared with the prepregnancy period, especially during the initial 3 months after delivery, whereas EDSS scores worsened during pregnancy and the postpartum period.
The odds of having memory worsening at follow-up after 3 years were almost 30% greater for those who exhibited deteriorating insomnia status than those who showed signs of improvement.
Similar to the recently commenced phase 2b LUMA study, BIIB122, an investigational small molecule inhibitor of LRRK2, will be evaluated in a cohort of 400 individuals with genetically mutated Parkinson disease.
The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses the biggest takeaway from the FDA approval of Amylyx’s therapy, marketed as Relyvrio, and the availability of the treatment for patients with ALS. [WATCH TIME: 5 minutes]
Data from a systemic review suggests that the COVID-19 pandemic is associated with increased rates of subthreshold insomnia symptoms, but not with moderate or severe insomnia, among the global population.
The division chief of stroke and vascular neurology at Duke Health discussed how clinicians have typically treated poststroke motor symptoms and how technology is expanding these capabilities.
New data from the NOVA trial showed differences in the number of T2 lesions in patients with relapsing-remitting multiple sclerosis at 72 weeks of treatment with natalizumab (Tysabri; Biogen), though seemingly driven by data from only 2 participants with extreme new or newly enlarging T2 hyperintense lesion numbers.
Valproic acid, which had been associated with a variety of major and minor malformations in pregnancy, remained barely unchanged in terms of use, dropping slightly from 12.4% to 10.1% over the 5-year period.
The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discussed updates in ALS research along with the need in future studies following AMX005’s (Relyvrio; Amylyx Pharmaceuticals) recent FDA approval. [WATCH TIME: 4 minutes]
A study using patient data from John Hopkins showed that rituximab treatment was associated with reduced annualized relapse rates in AQP4-IgG seropositive NMOSD and MOGAD.
The director of NYU Langone’s Alzheimer’s Disease Research Center and Center for Cognitive Neurology discussed current knowns and unknowns about the pathology of Alzheimer disease. [WATCH TIME: 4 minutes]
Joe Kardine, MS, OTR, CBIS, the clinical program manager at the Jefferson Center for Neurorestoration, discussed the influx of new neurorestorative technology and the future of treating patients with functional loss.
In a cohort of nearly 600,000 individuals, the combination of dementia diagnosis and presence of psychiatric comorbidity significantly increased the risk of suicide.
